Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome

European Journal of Pediatrics

Volumn 165, Issue 5, 2006, Pages 348-350

  Strnad Trojan, Nicola ^a   Linde, Richard ^a   Reichenbach, Janine ^a   Trojan, Jörg ^a   Zeuzem, Stefan ^b   Zielen, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Antiviral therapy; Chronic hepatitis C virus infection; Epstein Barr virus infection; Primary immunodeficiency; X linked lymphoproliferative syndrome

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANOREXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; EPSTEIN BARR VIRUS; FATIGUE; HEPATITIS C; HEPATITIS VIRUS; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MOOD CHANGE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VIRUS DIAGNOSIS;

ANTIVIRAL AGENTS; CHILD; DNA, VIRAL; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LYMPHOPROLIFERATIVE DISORDERS; RIBAVIRIN; RNA, VIRAL;

EID: 33645235832     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-005-0062-3     Document Type: Article

References (12)

1. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B cells in vivo. Immunity 9:395-404
2. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogamma-globulinemia after treatment with contaminated immune globulin. N Engl J Med 331:1607-1611
3. Bjøro K, Skaug K, Haaland T, Frøland SS (1999) Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. Q J Med 92:433-441
4. Chapel HM, Christie JM, Peach V, Chapman RW (2001) Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 99:320-324
5. Coffey AJ, Brooksbank RA, Brandau O et al. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20:129-135
6. Gershburg E, Pagano JS (2005) Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother 56:277-281
7. Gratama JW, Oosterveer MA, Zwaan FE, Lepoutre J, Klein G, Ernberg I (1988) Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci USA 85:8693-8696
8. NIH (2002) NIH consensus statement on management of hepatitis C (2002) NIH Consens State Sci Statements 19:1-46
9. Okano M, Pirruccello SJ, Grierson HL, Johnson DR, Thiele GM, Purtilo DT (1990) Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-alpha. Clin Immunol Immunopathol 54:410-418
10. Purtilo DT, Cassel CK, Yang JP, Harper R (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1:1935-1940
11. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C (2001) Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 101:284-288
12. Schuster V, Seidenspinner S, Grimm T et al. (1994) Molecular genetic haplotype segregation studies in three families with X-linked lymphoproliferative disease. Eur J Pediatr 153:432-437